HC Wainwright & Co. Maintains Buy on Roivant Sciences, Raises Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao maintains a Buy rating on Roivant Sciences (NASDAQ:ROIV) and raises the price target from $17 to $18.
April 03, 2024 | 11:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Roivant Sciences' Buy rating is maintained by HC Wainwright & Co., with the price target increased from $17 to $18.
The increase in price target by a reputable analyst firm like HC Wainwright & Co. typically signals a positive outlook on the company's future performance, potentially leading to increased investor confidence and a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100